TempraMed expects Q3 2026 sales to top Q3 2025 on July, August momentum
TempraMed forecast Q3 2026 sales will be significantly stronger than Q3 2025, citing continued commercial momentum. July sales reached US$522,000, a monthly record; August sales totaled US$403,000, the second-highest month to date. Sales for the eight months ended Aug. 31, 2026 were US$2.07 million, already above full